SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a number one most cancers diagnostics firm, introduced at present that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created management position designed to advance and scale the corporate’s world product improvement technique. Dr. Haas will be a part of Veracyte on March 24, 2026, and he can be liable for overseeing the corporate’s finish‑to‑finish product improvement, spanning diagnostic assay improvement, software program and bioinformatics, as effectively as the product improvement program workplace.
As Veracyte’s pipeline expands into entire‑genome minimal residual illness (MRD) and different multi‑omics functions, product improvement requires built-in capabilities throughout assays, software program, AI, and subsequent‑technology informatics to help options from prognosis to illness administration. In this position, Dr. Haas will lead these efforts to ship excessive‑high quality laboratory‑developed checks (LDTs) and world in vitro diagnostic (IVD) merchandise. He will deliver these capabilities collectively to speed up innovation and help the corporate’s world portfolio.
“Kevin is an accomplished product development and software leader with a track record of advancing diagnostic innovations and platform technologies,” stated Marc Stapley, Veracyte’s Chief Executive Officer. “His experience across software engineering, data science, and assay development will be critical as we execute on a growing pipeline of tests in development and expand our portfolio to benefit clinicians and patients worldwide.”
Dr. Haas has greater than 15 years of life sciences business expertise, main groups throughout expertise, analysis, and improvement. Most not too long ago, he served as Chief Technology Officer at Myriad Genetics, the place he led the event of the corporate’s precision medication platform and digital well being technique. Prior to that, Dr. Haas was Senior Vice President of Engineering at Myriad and Vice President of Bioinformatics at Myriad Women’s Health. Before becoming a member of Myriad, he held management roles in lab engineering and bioinformatics at Counsyl.
Dr. Haas has experience in creating automated lab expertise and AI methods to derive insights from genomics knowledge, and in launching scalable molecular assays. He obtained a B.S. from University of Wisconsin-Madison and a Ph.D. in chemical engineering from University of California-Berkeley, the place he labored on molecular simulation and machine studying to check protein dynamics.
“I am excited to join Veracyte at a time when the company is launching several exciting new tests, which is just the start of an incredibly strong development pipeline,” stated Dr. Haas. “The opportunity to help advance this breadth of innovation and development capabilities by bringing new diagnostic solutions for patients facing cancer is incredibly meaningful.”
About Veracyte
Veracyte (Nasdaq: VCYT) is a worldwide diagnostics firm whose imaginative and prescient is to rework most cancers look after sufferers everywhere in the world. We empower clinicians with the high-value insights they should information and guarantee sufferers at pivotal moments within the race to diagnose and deal with most cancers. Our Veracyte Diagnostics Platform delivers high-performing most cancers checks which can be fueled by broad genomic and medical knowledge, deep bioinformatic and AI capabilities, and a strong evidence-generation engine, which finally drives sturdy reimbursement and guideline inclusion for our checks, together with new insights to help continued innovation and pipeline improvement. For extra info, please go to www.veracyte.com or comply with us on LinkedIn or X (Twitter).
Cautionary Note Regarding Forward-Looking Statements
This press launch comprises forward-looking statements, together with, however not restricted to our statements associated to our plans, targets, expectations (monetary and in any other case) or intentions with respect to our medical checks in and exterior of the United States. Forward-looking statements will be recognized by phrases such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “positioned,” “designed” and related references to future intervals. Additional elements which will influence these forward-looking statements will be discovered beneath the caption “Risk Factors” in our Annual Report on Form 10-Ok filed on February 26, 2026, and our subsequent Quarterly Reports on Form 10-Q. Copies of those paperwork, when out there, could also be discovered within the Investors part of our web site at investor.veracyte.com. These forward-looking statements converse solely as of the date hereof and, besides as required by regulation, we particularly disclaim any obligation to replace these forward-looking statements or explanation why precise outcomes may differ, whether or not as a results of new info, future occasions or in any other case.